Ribociclib (Kisqali)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Cyclin-dependent kinase (CDK) 4 and 6 inhibitor. Ribociclib inhibits DNA synthesis and cancer cell growth by blocking activity of the cyclin D-CDK4/6 complex which regulates cell cycle progression and cellular proliferation by phosphorylating the retinoblastoma protein (pRb). Inhibiting pRb phosphorylation has been observed to lead to cell cycle arrest in the G1 phase.[1][2][3]
Route: PO
Extravasation: n/a

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 3/13/2017: Initial FDA approval "in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer."
  • 7/18/2018: FDA approval expanded "in combination with an aromatase inhibitor for pre/perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy." (no longer limited to postmenopausal women)

Also known as

  • Code names: LEE011, LEE-011
  • Brand name: Kisqali


  1. 1.0 1.1 Ribociclib (Kisqali) package insert
  2. Ribociclib (Kisqali) package insert (locally hosted backup)
  3. Kisqali manufacturer's website